EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure-based identification of small-molecule inhibitors that target the DIII domain of the Dengue virus glycoprotein E pan-serotypically

Prakhar Agrawal, Hemant Arya, Ganesan Senthil Kumar iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0311548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Prakhar Agrawal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Integrative Structural Biology Laboratory, National Institute of Immunology, New Delhi, India. Hauptthemen laut MEDLINE: Dengue Virus, Viral Envelope Proteins, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dengue viral infection is caused by the Dengue virus, which spreads to humans through the bite of infected mosquitos. Dengue affects over half of the global population, with an estimated 500 million infections per year. Despite this, no effective treatment is currently available, however, several promising candidates are undergoing pre-clinical/clinical testing. The existence of four major serotypes is an important challenge in the development of drugs and vaccines to combat Dengue virus infection. Hence, the drug/vaccine thereby developed should neutralize all the four serotypes equally. However, there is no pan-serotype specific treatment for Dengue virus, thereby emphasizing the need for the identification of novel drug-like compounds that can target all serotypes of the Dengue virus equally. To this end, we employed virtual screening methodologies to find drug-like compounds that target the domain III of glycoprotein E. Most importantly, domain III of E protein is involved in viral fusion with the host membrane and is also targeted by neutralizing antibodies. Our study found two small molecule drug-like compounds (out of the 3 million compounds screened) having similar binding affinity with all four serotypes. The compounds thereby identified exhibit favourable drug like properties and can be developed as a treatment for Dengue virus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dengue VirusViral Envelope ProteinsAntiviral AgentsSmall Molecule LibrariesSerogroupHumansMolecular Docking SimulationProtein DomainsDengue

Substanzen

Viral Envelope ProteinsAntiviral AgentsSmall Molecule Libraries

Autor:innen und Institutionen

  • Integrative Structural Biology Laboratory, National Institute of Immunology, New Delhi, India.

ORCID-Profile: Ganesan Senthil Kumar

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Agrawal, P., Arya, H., & Senthil Kumar, G. (2024). Structure-based identification of small-molecule inhibitors that target the DIII domain of the Dengue virus glycoprotein E pan-serotypically. PLOS ONE. https://doi.org/10.1371/journal.pone.0311548

Vancouver

Agrawal P, Arya H, Senthil Kumar G. Structure-based identification of small-molecule inhibitors that target the DIII domain of the Dengue virus glycoprotein E pan-serotypically. PLOS ONE. 2024. doi:10.1371/journal.pone.0311548

BibTeX
@article{Agrawal2024,
  author = {Agrawal, Prakhar and Arya, Hemant and Senthil Kumar, Ganesan},
  title = {Structure-based identification of small-molecule inhibitors that target the DIII domain of the Dengue virus glycoprotein E pan-serotypically},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0311548}
}
Kostenlos starten →